rs13900 — CCL2 CCL2 3'UTR variant

3'UTR variant that increases CCL2 mRNA stability via enhanced HuR binding, elevating MCP-1 protein output and monocyte recruitment in arterial inflammation

See your personal result for CCL2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CCL2 3'UTR — How mRNA Stability Amplifies Vascular Inflammation

Your genome contains not only the code for proteins but also regulatory sequences that control how long those messages survive inside cells. The rs13900 variant in the 3' untranslated region of CCL2 — the gene encoding monocyte chemoattractant protein-1 (MCP-1) — is one of these regulatory switches. rs13900 controls how long CCL2 mRNA survives before being degraded. A longer-lived message means more protein output even if transcription rates are identical.

The Mechanism

The rs13900 C-to-T transition in the CCL2 3' UTR alters the local RNA secondary structure in a way that enhances binding by [Human Antigen R (HuR) | HuR (ELAVL1) is a ubiquitous RNA-binding protein that stabilizes AU-rich element–containing mRNAs; it is a master regulator of inflammatory gene expression], an RNA-binding protein that stabilizes mRNAs by protecting them from nucleolytic degradation. Bioinformatic modeling predicts the T allele forms a stem-loop structure that presents a better binding surface for HuR than the C allele's predicted open conformation. Experimental validation confirmed approximately a seven-fold difference in HuR/antibody complex formation favoring the T allele (p<0.005). Nascent RNA decay experiments in heterozygous macrophage donors showed that T-allele CCL2 transcripts degrade significantly more slowly than C-allele transcripts from the same cell, with an overall CCL2 mRNA half-life of approximately 1.76 hours.

The Evidence

The foundational demonstration of rs13900's functional significance came from Pham et al. 2012 — 8 heterozygous donors for allelic expression imbalance (AEI) analysis11 Pham et al. 2012 — 8 heterozygous donors for allelic expression imbalance (AEI) analysis
Pham MH et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One. 2012;7(11):e49498. Using rs13900 as a transcribed proxy for the non-coding rs1024611 promoter variant, they showed that in every heterozygous individual examined, the T allele was expressed at significantly higher levels than the C allele (p=0.0009). This established that the G-T haplotype drives higher CCL2 output in vivo, not just in transfection systems.

The mechanistic detail was resolved by Akhtar et al. 2026 — 47 healthy individuals screened, 6 heterozygous donors used for stability analysis22 Akhtar et al. 2026 — 47 healthy individuals screened, 6 heterozygous donors used for stability analysis
Akhtar et al. The RNA-binding protein HuR modulates the expression of the disease-linked CCL2 rs1024611G-rs13900T haplotype. eLife. 2026, who confirmed that HuR preferentially binds T-allele transcripts in vitro (REMSA), ex vivo (RNA immunoprecipitation from primary macrophages), and that HuR overexpression selectively increases reporter activity for T-allele but not C-allele constructs (p<0.05). This places HuR as the molecular bridge between the rs13900 genotype and elevated CCL2 protein output.

The disease relevance of the CCL2-CCR2 signaling axis was directly demonstrated in a murine arteriogenesis model by Heil et al. 2004 — CCR2-knockout vs wild-type mice after femoral artery ligation33 Heil et al. 2004 — CCR2-knockout vs wild-type mice after femoral artery ligation
Heil M et al. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res. 2004;94(5):671-7. CCR2-deficient mice achieved only 47% of the blood flow recovery of wild-type controls (ratio 0.21 vs 0.45) after arterial occlusion, with dramatically reduced monocyte/macrophage infiltration into perivascular collateral spaces. This establishes that high CCL2-CCR2 signaling benefits collateral vessel remodeling in ischemia — a different dimension of the same inflammatory axis that drives atherosclerosis in the non-ischemic arterial wall.

At the clinical level, Gonzalez-Quesada & Frangogiannis 200944 Gonzalez-Quesada & Frangogiannis 2009
Gonzalez-Quesada C, Frangogiannis NG. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep. 2009;11(2):131-8 reviewed evidence that circulating MCP-1 levels provide independent prognostic information in acute coronary syndromes — higher levels correlating with greater atherosclerotic plaque burden and worse post-infarction remodeling outcomes.

Practical Actions

The rs13900 variant has no independent clinical guidelines or ClinVar classification — its clinical relevance derives from its perfect linkage disequilibrium with the better-studied rs1024611G promoter variant. Carriers of the CT or TT genotype share the high-output CCL2 haplotype and the associated inflammatory cardiovascular risk profile. For TT homozygotes, the priority is the same set of inflammatory and lipid biomarkers that characterize rs1024611 GG carriers: hs-CRP, lipoprotein(a), and blood pressure monitoring are the most genotype-relevant tests to prioritize in cardiovascular risk assessment.

Interactions

rs13900 and rs1024611 are in perfect linkage disequilibrium (D'=1.0, r²≈1.0) in European populations and act as proxies for each other.

The CCR2 receptor variant rs1799864 (V64I) modulates the downstream signaling efficiency of whatever CCL2 is produced. While this receptor variant showed no independent CAD association in the Wang 2011 meta-analysis, its interaction with the high-output CCL2 haplotype remains biologically plausible and warrants attention.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard CCL2 mRNA Stability Normal

Normal CCL2 mRNA stability — baseline MCP-1 protein output

The CC genotype at rs13900 corresponds to the common, lower-expression state of the CCL2 3' UTR. Without the T-allele stem-loop structure, HuR binds more weakly to CCL2 mRNA, resulting in standard transcript turnover rates. No post-transcriptional amplification of MCP-1 output occurs. Assuming the individual also carries the A allele at the perfectly LD promoter variant rs1024611 — which is almost always the case — CCL2 expression stays in the normal range under both basal and inflammatory conditions.

CT Elevated CCL2 mRNA Stability Intermediate

One T allele — moderately elevated CCL2 mRNA stability and MCP-1 output

The CT heterozygous state demonstrates allelic expression imbalance (AEI): even within a single cell that produces both alleles equally, the T-allele mRNA survives longer. Pham et al. 2012 demonstrated this in eight heterozygous individuals, observing T-allele predominance in every donor (p=0.0009). Akhtar et al. 2026 quantified the mechanistic basis: approximately sevenfold more HuR binds to T-allele compared to C-allele oligoribonucleotides.

TT High CCL2 mRNA Stability High Risk

Two T alleles — highest CCL2 mRNA stability and maximum post-transcriptional MCP-1 amplification

As a TT homozygote, both CCL2 transcript copies carry the T-allele secondary structure, conferring maximum HuR recruitment and mRNA stabilization. Akhtar et al. 2026 established this mechanism through multiple converging assays: RNA electrophoretic mobility shift (~7-fold difference, p<0.005) and RNA immunoprecipitation from primary macrophages. In the context of vascular biology, sustained elevated MCP-1 production lowers the threshold for monocyte migration into arterial walls, accelerating foam cell formation and atherosclerotic plaque development. The same pathway also shows its dual nature: in ischemic settings, CCL2-driven monocyte recruitment to collateral arteries is essential for arteriogenesis (Heil et al. 2004 CCR2-knockout mouse model).

Disease associations documented for the rs1024611G-rs13900T haplotype include HIV-associated neurocognitive disorder, pulmonary tuberculosis, atherosclerosis, myocardial infarction, and asthma.